07 Feb General Update (CYP2C19)
General Update
GenXys is one of the first groups to update our comprehensive precision prescribing algorithm to include the latest release from the Clinical Pharmacogenetics Implementation Consortium (CPIC) CYP2C19 Genotype and Clopidogrel Therapy, published January 19, 2022.
We stay at the cutting-edge of research and are constantly revamping our algorithm to stay current and ahead of the pack. This recent information informs metabolism which is a key component of drug absorption and thus efficacy. Genxys is constantly working to lead precision prescribing by bringing together relevant data points including current medical conditions and comorbidities, liver and kidney function, previous medications and drug interactions. We are also highly focused on the genetic makeup of our patients, so it is important to stay topical and integrate new data in real time.
To learn more about it, visit Lee, C.R., Luzum, J.A., Sangkuhl, K., Gammal, R.S., Sabatine, M.S., Stein, C.M., Kisor, D.F., Limdi, N.A., Lee, Y.M., Scott, S.A., Hulot, J.-S., Roden, D.M., Gaedigk, A., Caudle, K.E., Klein, T.E., Johnson, J.A. and Shuldiner, A.R. (2022), Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clinical Pharmacology & Therapeutics. Accepted Author Manuscript. https://doi.org/10.1002/cpt.2526
Sorry, the comment form is closed at this time.